Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics
GET POWR RATINGS... FREE!
RIGL POWR Grades
- Value is the dimension where RIGL ranks best; there it ranks ahead of 90.36% of US stocks.
- The strongest trend for RIGL is in Momentum, which has been heading down over the past 31 weeks.
- RIGL's current lowest rank is in the Stability metric (where it is better than 4.08% of US stocks).
RIGL Stock Summary
- For RIGL, its debt to operating expenses ratio is greater than that reported by merely 21.52% of US equities we're observing.
- In terms of twelve month growth in earnings before interest and taxes, Rigel Pharmaceuticals Inc is reporting a growth rate of -70.92%; that's higher than 25.01% of US stocks.
- Revenue growth over the past 12 months for Rigel Pharmaceuticals Inc comes in at 30.71%, a number that bests 82.88% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Rigel Pharmaceuticals Inc are FLXS, CARS, CHX, HSII, and DHX.
- Visit RIGL's SEC page to see the company's official filings. To visit the company's web site, go to www.rigel.com.
RIGL Valuation Summary
- In comparison to the median Healthcare stock, RIGL's price/sales ratio is 56.12% lower, now standing at 5.2.
- RIGL's price/sales ratio has moved down 16.4 over the prior 243 months.
- RIGL's price/sales ratio has moved down 16.4 over the prior 243 months.
Below are key valuation metrics over time for RIGL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RIGL | 2021-03-04 | 5.6 | 17.9 | -20.5 | -21.7 |
| RIGL | 2020-03-02 | 6.1 | 6.8 | -5.4 | -5.7 |
| RIGL | 2015-11-25 | 9.9 | 2.9 | -4.6 | -4.0 |
| RIGL | 2010-01-20 | NA | 3.7 | -4.0 | -3.2 |
| RIGL | 2008-02-12 | 87.7 | 7.2 | -9.6 | -9.1 |
| RIGL | 2004-12-08 | 80.1 | 7.5 | -8.6 | -8.6 |
RIGL Growth Metrics
- Its year over year net cashflow from operations growth rate is now at -56.8%.
- The year over year price growth rate now stands at 77.04%.
- Its 4 year price growth rate is now at -28.47%.
The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 133.878 | -69.047 | -11.487 |
| 2020-12-31 | 108.621 | -52.185 | -29.744 |
| 2020-09-30 | 105.571 | -46.262 | -27.707 |
| 2020-06-30 | 108.039 | -41.421 | -25.023 |
| 2020-03-31 | 102.425 | -44.034 | -28.053 |
| 2019-12-31 | 59.288 | -41.51 | -66.894 |
RIGL Price Target
For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.50 | Average Broker Recommendation | 1.33 (Strong Buy) |
RIGL Stock Price Chart Interactive Chart >
RIGL Price/Volume Stats
| Current price | $4.06 | 52-week high | $5.50 |
| Prev. close | $4.08 | 52-week low | $2.14 |
| Day low | $3.96 | Volume | 882,695 |
| Day high | $4.12 | Avg. volume | 2,938,406 |
| 50-day MA | $4.08 | Dividend yield | N/A |
| 200-day MA | $3.63 | Market Cap | 690.87M |
Rigel Pharmaceuticals, Inc. (RIGL) Company Bio
Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.
Latest RIGL News From Around the Web
Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
3 Biotech Stocks That Could Rocket HigherOver the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming. |
New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 CongressRigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place online from July 17 – 21, 2021. |
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Can A Stock Thats Up 2.6% YTD Still Be Considered In Loss Territory?During the last session, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)s traded shares were 777,538, with the beta value of the company hitting 1.5. At the end of the trading day, the stocks price was $4.41, reflecting an intraday loss of -2% or -$0.09. The 52-week high for the RIGL share is $5.5, that puts it down -24.72% [] |
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical TrialSOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company''s novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) ACTIV-4 (Accelerating |
Rigel''s Fostamatinib Selected for NIH ACTIV-4 COVID-19 TrialRigel Pharmaceuticals Inc''s (NASDAQ: RIGL ) fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, has been |
RIGL Price Returns
| 1-mo | -10.57% |
| 3-mo | 7.41% |
| 6-mo | 16.67% |
| 1-year | 56.15% |
| 3-year | 44.48% |
| 5-year | 73.50% |
| YTD | 16.00% |
| 2020 | 63.55% |
| 2019 | -6.96% |
| 2018 | -40.72% |
| 2017 | 63.03% |
| 2016 | -21.45% |
Continue Researching RIGL
Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...